Research Analysts Issue Forecasts for MLTX FY2026 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright lowered their FY2026 EPS estimates for shares of MoonLake Immunotherapeutics in a research report issued to clients and investors on Monday, November 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($3.58) per share for the year, down from their prior estimate of ($3.17). HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q4 2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($0.79) EPS, Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.63) EPS and FY2027 earnings at ($3.01) EPS.

Other equities research analysts have also recently issued reports about the company. Chardan Capital assumed coverage on MoonLake Immunotherapeutics in a research note on Friday, November 6th. They issued a “buy” rating and a $57.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, September 16th. Wall Street Zen lowered shares of MoonLake Immunotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, September 27th. Finally, Weiss Ratings upgraded shares of MoonLake Immunotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.09.

MoonLake Immunotherapeutics Stock Down 0.5%

MLTX stock opened at $12.56 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 9.13 and a current ratio of 9.13. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -3.42 and a beta of 1.14. MoonLake Immunotherapeutics has a fifty-two week low of $9.46 and a fifty-two week high of $23.29. The stock has a fifty day moving average of $12.01 and a 200-day moving average of $16.29.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.10).

Institutional Trading of MoonLake Immunotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Weiss Asset Management LP grew its holdings in MoonLake Immunotherapeutics by 413.1% during the 1st quarter. Weiss Asset Management LP now owns 1,708,328 shares of the company’s stock valued at $31,843,000 after buying an additional 1,375,367 shares in the last quarter. Janus Henderson Group PLC increased its holdings in MoonLake Immunotherapeutics by 64.7% during the 1st quarter. Janus Henderson Group PLC now owns 3,451,628 shares of the company’s stock worth $64,304,000 after acquiring an additional 1,355,640 shares during the period. Bank of America Corp DE lifted its stake in MoonLake Immunotherapeutics by 5,255.8% in the 1st quarter. Bank of America Corp DE now owns 724,794 shares of the company’s stock worth $13,510,000 after purchasing an additional 711,261 shares in the last quarter. Exome Asset Management LLC purchased a new stake in MoonLake Immunotherapeutics in the 1st quarter worth approximately $4,015,000. Finally, Readystate Asset Management LP purchased a new stake in MoonLake Immunotherapeutics in the 1st quarter worth approximately $2,689,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a Switzerland-based clinical-stage biopharmaceutical company focused on developing treatments for inflammatory skin and joint diseases. The company was established in 2021 and is headquartered in Zug. Its lead investigational medicine, sonelokimab, is a nanobody designed to inhibit the inflammatory proteins IL-17A and IL-17F. MoonLake is studying the drug as a potential treatment for conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis.